Individual-level attribution modeling reveals that real-world semaglutide effectiveness is not a fixed property of the molecule, but an interaction between pharmacological exposure and modifiable care ...

Viking Therapeutics, Inc. aces hurdles for obesity drug VK2735 vs. Zepbound/Wegovy—tolerability, weak differentiation, and competition. Click for this VKTX update.

BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.

Novo Nordisk A/S shares plunged ~25% after sharply lowered 2026 revenue and profit guidance. Learn more about NOVO:CA stock here.

Author - Dr Sanjay Agarwal, HOD, Diabetes, Obesity & Metabolic Diseases, Sahyadri Super Speciality Hospital, Nagar Road, Pune and secretary general, of RSSDI.

The FDA has outlined numerous concerns about the sale and use of unapproved GLP-1 drugs for weight loss.  “FDA is aware that ...

Pfizer Inc. (NYSE:PFE) Q4 2025 Earnings Call Transcript February 3, 2026 Pfizer Inc. beats earnings expectations. Reported ...

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

The gray market is awash with BPC-157, a drug hyped as a cure-all, but unapproved by the FDA. Will RFK Jr. change that?

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2026 Earnings Call Transcript February 3, 2026 Operator: Good day, everyone. And ...

An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context, published pricing disclosures, telehealth ...

Bacteria incubated with bacteriophages in space accumulated distinct mutations compared to those on Earth, highlighting the ...